Literature DB >> 7459271

Colchicine in the treatment of the cutaneous manifestations of Behçet's disease.

Y Miyachi, S Taniguchi, M Ozaki, T Horio.   

Abstract

Five patients with Behçet's disease were satisfactorily treated with colchicine. Oral aphthosis, erythema nodosum-like lesions and genital erosions improved greatly within a month as did laboratory findings. We believe colchicine to be the first choice in the management of the cutaneous and ocular lesions of Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7459271     DOI: 10.1111/j.1365-2133.1981.tb01713.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation.

Authors:  Andrew P Demidowich; Angela I Davis; Nicket Dedhia; Jack A Yanovski
Journal:  Med Hypotheses       Date:  2016-04-25       Impact factor: 1.538

2.  Colchicine in Behçet's disease with major vessel thrombosis.

Authors:  G Celik; O Kalaycioğlu; G Durmaz
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 3.  Uveitis. A review.

Authors:  C Y Lowder; D H Char
Journal:  West J Med       Date:  1984-03

4.  Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial.

Authors:  Maria Angela Martins Mimura; Silvio Kenji Hirota; Norberto Nobuo Sugaya; José Antonio Sanches; Dante Antonio Migliari
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.